# LABORATORY BIOMARKERS FOR CARDIOVASCULAR DISEASE RISK STRATIFICATION: A NARRATIVE REVIEW

**Salah Omar Alshamkhi[1]*, Sahar Rmadan Bafna[2], Faisal Melhag Alotaibi[1], Mohammed Awadh Salem Alshehri[3], Abdullrhman Abdullaziz Alhusini[4], Hassan Abdullah Mohd Abu Hussien[4], Zaid Saeed Saleh Alwaked[4], Bader Musfer Saad Aldosary[5], Turky Ashwi Aqeel Alanazi[4], Reem Saad Altalal[4], Majed Abdullah Saleh Alyahya[6], Anwar Mallah Ali Alanazi[7], Abdul Rahman Jahaz Al-Otaibi[8]**

**Abstract**

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally, necessitating effective risk stratification strategies for optimal management and prevention. This narrative review explores the role of laboratory biomarkers in CVD risk assessment, encompassing lipid biomarkers (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides), inflammatory biomarkers (C-reactive protein, interleukins, tumor necrosis factor-alpha), cardiac biomarkers (troponin, B-type natriuretic peptide, myeloperoxidase), hemostatic biomarkers (fibrinogen, D-dimer), metabolic biomarkers (hemoglobin A1c, insulin, adiponectin, leptin), and genetic biomarkers (apolipoprotein E genotype, familial hypercholesterolemia genes, single nucleotide polymorphisms related to CVD).

The utility of individual biomarkers versus multimarker panels, integration of biomarkers into risk assessment models, and their application in specific populations such as women and the elderly are discussed. Challenges including standardization of biomarker measurement, interpretation of biomarker levels, cost-effectiveness, and accessibility are highlighted, along with strategies to overcome bias and confounding factors. Future directions focus on novel biomarkers in the research pipeline, integration of omics technologies (genomics, proteomics, metabolomics), and personalized medicine approaches for enhanced risk prediction and tailored interventions.

**Keywords:** cardiovascular disease, biomarkers, risk assessment, lipid biomarkers, inflammatory biomarkers, cardiac biomarkers.

[1]*Laboratory Technician, Directorate Of Health Affairs, Jeddah, Saudi Arabia
[2]Laboratoy Technician, Jeddah First Health Cluster, Jeddah Regional Lab, Saudi Arabia
[3]Lab Technician, King Saud Medical City, Riyadh, Saudi Arabia
[4]Lab.Technician, Regional Laboratory And Blood Bank, Riyadh, Saudi Arabia
[5]Lab Technician, Central Blood Bank
[6]Specialist Of Laboratory, Regional Laboratory And Blood Bank, Riyadh, Saudi Arabia
[7]Senior Lab Specialist, Regional Laboratory And Blood Bank, Riyadh, Saudi Arabia
[8]Laboratory Technician, Afif General Hospital, Riyadh, Saudi Arabia

***Corresponding Author:** Salah Omar Alshamkhi
*Laboratory Technician, Directorate Of Health Affairs, Jeddah, Saudi Arabia

**DOI:** 10.53555/ecb/2022.11.10.126

## I. Introduction

Cardiovascular diseases (CVDs) constitute a significant global health burden, accounting for a substantial number of deaths each year [1]. CVD encompasses a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, stroke, and peripheral artery disease. These conditions collectively contribute to a high morbidity and mortality rate worldwide, making CVD a primary focus of public health efforts and medical research [2,3].

The underlying mechanisms of CVD are complex and multifactorial, often involving a combination of genetic predispositions and modifiable risk factors. Lifestyle factors such as diet, physical activity, and tobacco use play crucial roles in the development and progression of CVD [4]. Moreover, advancements in medical technology and treatment modalities have improved outcomes for individuals with CVD, emphasizing the importance of early detection and risk stratification [4-6].

Risk stratification in CVD refers to the process of evaluating an individual's risk of developing cardiovascular events based on various clinical parameters and biomarkers. This risk assessment aids in identifying high-risk individuals who may benefit from targeted interventions, such as lifestyle modifications, pharmacological therapies, or invasive procedures [2,7]. By stratifying individuals into different risk categories, healthcare providers can tailor preventive strategies to each patient's specific needs, thereby optimizing outcomes and reducing overall disease burden [8].

Biomarkers are measurable indicators of biological processes or disease states that can provide valuable information about an individual's health status. In the context of CVD risk assessment, biomarkers play a crucial role in identifying underlying pathophysiological mechanisms, predicting future cardiovascular events, and monitoring treatment responses. These biomarkers can be derived from various sources, including blood samples, imaging studies, and genetic analyses [9,10].

The integration of biomarkers into risk assessment models enhances their predictive accuracy and allows for a more comprehensive evaluation of cardiovascular risk. By incorporating biomarker data alongside traditional risk factors, clinicians can obtain a more nuanced understanding of an individual's risk profile, leading to more informed clinical decision-making and improved patient outcomes [8,11].

## II. Traditional Risk Factors for CVD

### A. Hypertension

Hypertension, characterized by elevated blood pressure levels, is a well-established risk factor for CVD. Chronic hypertension can lead to structural changes in the blood vessels, increasing the risk of atherosclerosis, coronary artery disease, and stroke [2,12]. The mechanisms linking hypertension to CVD involve endothelial dysfunction, vascular inflammation, and hemodynamic alterations that contribute to myocardial remodeling and dysfunction over time [12].

### B. Hyperlipidemia

Hyperlipidemia, specifically elevated levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides, is another significant risk factor for CVD. High levels of LDL-C promote the formation of atherosclerotic plaques within the arterial walls, narrowing the blood vessels and impairing blood flow to vital organs. Similarly, elevated triglyceride levels are associated with increased cardiovascular risk, particularly in individuals with metabolic syndrome or diabetes mellitus [1-3].

### C. Diabetes Mellitus

Diabetes mellitus, both type 1 and type 2, significantly increases the risk of developing CVD. The metabolic abnormalities associated with diabetes, including insulin resistance, hyperglycemia, and dyslipidemia, contribute to accelerated atherosclerosis and endothelial dysfunction. Individuals with diabetes often exhibit a clustering of cardiovascular risk factors, highlighting the importance of aggressive risk factor modification and glycemic control in this population [2,4,13].

### D. Smoking

Cigarette smoking is a well-established modifiable risk factor for CVD, exerting deleterious effects on cardiovascular health through various mechanisms. Smoking promotes endothelial dysfunction, oxidative stress, inflammation, and thrombosis, all of which contribute to the development and progression of atherosclerosis and coronary artery disease. Smoking cessation remains a cornerstone of CVD prevention and risk reduction [13,14].

### E. Age and Gender

Advancing age is a non-modifiable risk factor for CVD, with the incidence and prevalence of cardiovascular events increasing with age. Age-related changes in vascular structure and function, along with cumulative exposure to other risk factors over time, contribute to the elevated risk observed in older individuals. Additionally, gender

differences exist in the manifestation and presentation of CVD, with women often experiencing cardiovascular events at a later age compared to men but exhibiting poorer outcomes post-event [14-17].

## III. Biomarkers for CVD Risk Assessment

### A. Lipid Biomarkers

Lipid biomarkers are fundamental in assessing cardiovascular risk due to their association with atherosclerosis and coronary artery disease [18]. Total cholesterol, comprising LDL cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides, serves as a cornerstone in risk prediction models. Elevated LDL-C levels are particularly concerning as they contribute to plaque formation in arterial walls, leading to atherosclerosis and increased risk of cardiovascular events [19]. On the other hand, HDL-C is often considered protective against CVD due to its role in reverse cholesterol transport, promoting the removal of cholesterol from peripheral tissues and arteries [18].

### B. Inflammatory Biomarkers

Inflammation plays a crucial role in the pathogenesis of atherosclerosis and CVD. C-reactive protein (CRP) is one of the most studied inflammatory biomarkers and is associated with increased cardiovascular risk, particularly in individuals with underlying inflammatory conditions such as rheumatoid arthritis or systemic lupus erythematosus [18,20]. Interleukins (IL-6, IL-10) and tumor necrosis factor-alpha (TNF-alpha) are also implicated in the inflammatory processes underlying atherosclerosis, providing further insights into the systemic inflammatory burden and its impact on cardiovascular health [20].

### C. Cardiac Biomarkers

Cardiac biomarkers are indicative of myocardial injury or stress and are commonly used in the diagnosis and risk assessment of acute coronary syndromes (ACS) and heart failure. Troponin, a sensitive and specific marker of myocardial damage, is elevated in conditions such as myocardial infarction and unstable angina, reflecting ongoing cardiac injury [21,22]. B-type natriuretic peptide (BNP) and its N-terminal prohormone (NT-proBNP) are markers of ventricular wall stress and are elevated in heart failure, providing valuable prognostic information. Myeloperoxidase (MPO) is an emerging biomarker associated with plaque instability and endothelial dysfunction, contributing to CVD risk prediction [18,21].

### D. Hemostatic Biomarkers

Hemostatic biomarkers reflect the balance between thrombosis and fibrinolysis and are relevant in assessing cardiovascular risk, especially in individuals with a prothrombotic phenotype. Fibrinogen, a key player in the coagulation cascade, is associated with increased risk of thrombotic events, including myocardial infarction and stroke. D-dimer, a marker of fibrinolysis and thrombus formation, is elevated in conditions such as venous thromboembolism and may have prognostic value in certain cardiovascular disorders [18,22].

### E. Metabolic Biomarkers

Metabolic biomarkers provide insights into metabolic dysregulation and insulin resistance, which are linked to increased cardiovascular risk. Hemoglobin A1c (HbA1c), a marker of long-term glycemic control in diabetes, is associated with atherosclerosis and cardiovascular complications. Insulin levels, along with adiponectin and leptin, reflect adipose tissue function and metabolic health, influencing cardiovascular risk through mechanisms such as inflammation, insulin resistance, and lipid metabolism [21,23].

### F. Genetic Biomarkers

Genetic biomarkers offer a personalized approach to cardiovascular risk assessment by identifying individuals with genetic predispositions to CVD. The apolipoprotein E (APOE) genotype, for instance, influences cholesterol metabolism and is associated with varying degrees of cardiovascular risk. Familial hypercholesterolemia (FH) genes, such as LDL receptor (LDLR) mutations, predispose individuals to early-onset hypercholesterolemia and premature CVD [24]. Single nucleotide polymorphisms (SNPs) related to CVD, including those involved in lipid metabolism, inflammation, and thrombosis, further contribute to risk stratification and personalized preventive strategies [24,25].

## IV. Utility of Biomarkers in CVD Risk Prediction

### A. Individual Biomarkers vs. Multimarker Panels

The use of individual biomarkers in CVD risk prediction has been the traditional approach, with markers such as LDL cholesterol or C-reactive protein (CRP) providing valuable insights into specific aspects of cardiovascular health. However, the limitations of individual biomarkers, including their variable predictive power and reliance on specific pathophysiological pathways, have led to the development of multimarker panels [22]. These

panels combine multiple biomarkers from different biological pathways, enhancing the accuracy and robustness of risk prediction models. By integrating lipid biomarkers, inflammatory markers, cardiac biomarkers, and genetic markers, multimarker panels offer a more comprehensive assessment of cardiovascular risk, allowing for tailored preventive strategies based on an individual's unique risk profile [8,12,24].

**B. Risk Assessment Models Incorporating Biomarkers**

Risk assessment models that incorporate biomarkers have gained prominence in cardiovascular medicine, with established scoring systems such as the Framingham Risk Score and the American College of Cardiology/American Heart Association (ACC/AHA) risk calculator integrating biomarker data alongside traditional risk factors. These models utilize statistical algorithms to estimate an individual's absolute risk of experiencing a cardiovascular event over a specified time period, guiding clinical decision-making regarding treatment intensity and preventive measures [8,16,23,34]. The incorporation of biomarkers into risk assessment models improves risk stratification accuracy, particularly in intermediate-risk individuals where clinical judgment alone may be insufficient to guide management [22-25].

**C. Biomarkers in Specific Populations (e.g., Women, Elderly)**

Biomarkers play a crucial role in risk prediction within specific populations, such as women and the elderly, where traditional risk factors may manifest differently or carry varying prognostic implications. For example, sex-specific biomarkers like pregnancy-associated plasma protein-A (PAPP-A) or sex hormone-binding globulin (SHBG) may provide additional insights into cardiovascular risk in women beyond traditional risk factors [21,24,25]. Similarly, biomarkers of aging-related processes, such as telomere length or senescence markers, are being explored for their utility in predicting cardiovascular outcomes in the elderly population. Tailoring risk assessment strategies to account for population-specific biomarker profiles can enhance the precision of cardiovascular risk prediction and improve clinical outcomes [18,19,25].

## V. Challenges and Limitations

One of the primary challenges in utilizing biomarkers for CVD risk prediction is the lack of standardized measurement techniques and reference ranges across different laboratories and assay platforms. Variability in assay methodologies, calibration standards, and sample handling procedures can lead to discrepancies in biomarker results, compromising their reliability and comparability across studies [17,20,22].

Interpreting biomarker levels in the context of cardiovascular risk assessment requires careful consideration of confounding factors, comorbidities, and temporal changes. Biomarkers may exhibit dynamic fluctuations in response to acute illnesses, medications, or lifestyle interventions, necessitating longitudinal monitoring and contextual interpretation to avoid misclassification of risk [21,23].

**C. Cost-effectiveness and Accessibility**

The cost-effectiveness and accessibility of biomarker testing pose practical challenges in clinical practice, especially in resource-limited settings or populations with limited healthcare access. High-cost biomarker assays or specialized testing platforms may not be readily available or affordable for widespread use, limiting their utility in routine risk assessment and population-based screening programs [6,10,17].

**D. Overcoming Bias and Confounding Factors**

Accounting for potential biases and confounding factors is essential when incorporating biomarkers into risk prediction models. Bias due to selection criteria, participant demographics, or disease prevalence can influence the generalizability of biomarker-based risk assessments [16,20]. Additionally, confounding variables such as socioeconomic status, lifestyle factors, and comorbidities must be appropriately adjusted for to ensure accurate risk stratification.

## VI. Conclusion

In summary, biomarkers play a pivotal role in cardiovascular disease risk prediction by enhancing risk stratification accuracy, guiding clinical decision-making, and identifying high-risk individuals who may benefit from targeted interventions. From lipid and inflammatory biomarkers to genetic and omics-based profiles, the landscape of biomarker research in CVD continues to expand, offering new insights into disease pathophysiology and therapeutic opportunities. The incorporation of biomarkers into clinical practice requires overcoming challenges related to standardization, interpretation, cost-effectiveness, and bias, while leveraging emerging technologies and personalized medicine approaches. Biomarker-driven risk assessment models and multimarker panels offer a holistic view of cardiovascular risk, enabling clinicians to implement preventive

strategies tailored to individual patient needs. Future research directions in biomarker discovery and validation encompass exploring novel biomarkers, integrating omics technologies, refining risk prediction models, and validating personalized medicine approaches in diverse patient populations. Collaborative efforts between researchers, clinicians, and industry stakeholders are essential to translate biomarker discoveries into clinical practice and improve cardiovascular outcomes on a global scale.

## VII. References


1. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D. European Society of Cardiology: cardiovascular disease statistics 2021. European heart journal. 2022 Feb 21;43(8):716-99.
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-596.
3. Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, Gale CP, Achenbach S, Weidinger F, Vardas P. Epidemiology of cardiovascular disease in Europe. Nature Reviews Cardiology. 2022 Feb;19(2):133-43.
4. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian Journal of Cardiology. 2018 May 1;34(5):575-84.
5. Katakami N. Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. Journal of atherosclerosis and thrombosis. 2018 Jan 1;25(1):27-39.
6. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World journal of diabetes. 2015 Oct 10;6(13):1246.
7. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith Jr SC, Sperling LS, Virani SS, Blumenthal RS. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. Circulation. 2019 Jun 18;139(25):e1162-77.
8. Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA cardiology. 2017 Jun 1;2(6):635-43.
9. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. Journal of geriatric cardiology: JGC. 2017 Feb;14(2):135.
10. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. Journal of lipids. 2015 Oct;2015.
11. Yeboah J, Young R, McClelland RL, Delaney JC, Polonsky TS, Dawood FZ, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. Journal of the American College of Cardiology. 2016 Jan 19;67(2):139-47.
12. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacological research. 2018 Mar 1;129:95-9.
13. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JW. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. European journal of preventive cardiology. 2019 Dec;26(2_suppl):25-32.
14. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet. 2020 Mar 7;395(10226):795-808.
15. Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart views. 2017 Jul 1;18(3):109-14.
16. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. Journal of the American College of Cardiology. 2019 Nov 19;74(20):2529-32.
17. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, Mente A, Yusuf S. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circulation research. 2017 Sep 1;121(6):677-94.
18. Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends in cardiovascular medicine. 2017 Feb 1;27(2):123-33.

19. Thomas MR, Lip GY. Novel risk markers and risk assessments for cardiovascular disease. Circulation research. 2017 Jan 6;120(1):133-49.
20. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. Journal of lipids. 2015 Oct;2015.
21. Hafiane A, Genest J. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA clinical. 2015 Jun 1;3:175-88.
22. Ho JE, Lyass A, Courchesne P, Chen G, Liu C, Yin X, Hwang SJ, Massaro JM, Larson MG, Levy D. Protein biomarkers of cardiovascular disease and mortality in the community. Journal of the American heart association. 2018 Jul 17;7(14):e008108.
23. Sun J, Axelsson J, Machowska A, Heimbürger O, Bárány P, Lindholm B, Lindström K, Stenvinkel P, Qureshi AR. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clinical Journal of the American Society of Nephrology. 2016 Jul 1;11(7):1163-72.
24. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. Journal of geriatric cardiology: JGC. 2017 Feb;14(2):135.
25. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I, Vartiainen E, Sans S, Pasterkamp G, Hughes M, Costanzo S. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017 Oct 24;136(17):1588-97.